Gilead Sciences (GILD) is a pharmaceutical drug company that produces highly effective drugs to treat infectious diseases. We think GILD is a great company, that makes great products whose stock trades at a very reasonable price. We first recommended that readers take a position in the company with a buy-write strategy back on 5-January-2017. The stock had sold off from a high of about $125 in the middle of 2017, and it looked like it was forming a base in the $70 zone. The company had (and still does) a number of drugs in Phase III trials, but results were not due for some time. Since GILD paid a dividend, and regularly repurchases shares, we felt that selling premium for additional income was a conservative strategy as we wait for drug approvals to roll in.
